NCT01242449已完成2 期
A Phase II Investigation of Oral Vinorelbine in Combination With Trastuzumab for 1st and 2nd Line Treatment of Women With Metastatic HER2 Positive Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 6
- 主要终点
- Objective Response Rate
研究概览
简要总结
This phase II study will investigate oral vinorelbine 90 mg/m2 on days 1 + 8 at 3 weeks intervals in combination with trastuzumab as 1st and 2nd line treatment of women with metastatic HER2 positive breast cancer.
Oral vinorelbine has shown the same overall response rate as i.v. vinorelbine in metastatic breast cancer, and capsules are generally better tolerated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Woman ≥ 18 years of age.
- •Expected lifetime of more than 12 weeks.
- •Histologically verified breast cancer(adenocarcinoma)
- •Primary tumor or metastasis is HER2 positive with IHC3+ or FISH+ (ratio ≥ 2.2).
- •Documented metastatic breast cancer with min. one lesion measureable according to the RECIST 1.1 criteria. All solitary lesions must be verified cytologically/histologically if representing the only evidence of malignancy.
- •The patient may have received (neo-) adjuvant chemotherapy (taxanes, anthracyclines and trastuzumab) and 1st line chemotherapy in combination with trastuzumab for metastatic disease.
- •The patient may have received previous adjuvant antihormonal treatment for metastatic breast cancer.
- •The patient may receive radiation therapy, however, not against lesions used for response evaluation.
- •Normal heart function, LVEF ≥ 50% measured by MUGA/EKKO.
- •Normal bone marrow function: Hemoglobin ≥ 6 mmol/l, ANC ≥ 1.5x10^9/l. Thrombocytes ≥ 100x10^9/l.
- •Normal liver function: Bilirubin ≤ 1.5 x upper normal level, ALAT ≤ 2.5 x upper normal level, BASP ≤ 2.5 x upper normal level (≤ 5 if presence of bone metastases).
- •Normal renal function: Creatinine ≤ upper normal level. In case of raised creatinine the measured/calculated GFR must be ≥ 50 ml/min.
- •Fertile women must present a negative pregnancy test and use contraceptives during and 3 months after treatment. An IUD without hormone is considered a safe contraceptive.
- •Written and orally informed consent prior to any study related procedure.
排除标准
- •Local recurrence or counter-lateral breast cancer without other dissemination.
- •Pregnant or breastfeeding women.
- •Clinical symptoms of CNS metastases, incl. meningeal carcinomatosis.
- •Malabsorption syndrome or other disease affecting the gastrointestinal function. Resection of the ventriculus or the small intestine, which can affect absorption of oral vinorelbine.
- •Dysphagia or other conditions preventing the patient from swallowing tablets.
- •Mental or social conditions preventing treatment or follow-up.
- •Serious concurrent medical condition, such as:
- •AMI within 12 months or unstable angina.
- •Heart incompensation NYHA III or IV or uncontrolled hypertension (systolic > 150 mm/hg and/or diastolic >100 mm/hg).
- •Serious arrythmia requiring medication, excl. atrial fibrillation and paroxystic supraventricular tachycardia.
- •Active infection, uncontrolled diabetes or hypercalcemia.
- •Other concurrent experimental treatment.
- •Concurrent antihormonal treatment of metastatic breast cancer.
- •Known neuropathia ≥ grade
- •Other previous malignant disease within the past 5 years excl. non-melanoma skin cancer and carcinoma in situ cervicis uteri.
- •Previous treatment with vinca alkaloid.
- •Previous serious allergic or unexpected reactions to trastuzumab treatment.
结局指标
主要结局
Objective Response Rate
时间窗: Every 9 weeks. Up to 2 years
CT scan and MUGA scan
次要结局
- Progression free survival(Every 9 weeks from date of first treatment until progression or death. Up to 2 years)
- Overall Survival(From date of inclusion until date of death. Up to 2 years.)
研究者
研究点 (6)
Loading locations...
相似试验
进行中（未招募）
1 期
Ensayo clínico en fase I-II de vinorelbina oral (Navelbine) en combinación con capecitabina en tratamiento de primera línea en pacientes con cáncer de mama avanzado - Not applicableAdvanced breast cancer (metastatic)EUCTR2004-000602-44-ESPierre Fabre Ibérica, S.A.63
进行中（未招募）
1 期
Study to assess the efficacy and safety of oral vinorelbine in combination with capecitabine in patients suffering from breast cancer previously treated with other chemotherapies (anthracyclines, and taxanes)EUCTR2004-000665-35-ESPierre Fabre Medicament
进行中（未招募）
1 期
Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer. - Not applicableEUCTR2004-000748-26-ESPierre Fabre Ibérica, S.A. en representación de Pierre Fabre Mèdicament55
进行中（未招募）
1 期
Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer. - Not applicableTreatment in women with previously untreated HER2 negative metastatic breast cancer.EUCTR2004-000753-30-ESPierre Fabre Ibérica S.A. as legal representative of Pierr Fabre Mèdicament55
已完成
1 期
Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT00702182National Cancer Centre, Singapore30